

Supplementary Figure S1 Observed and simulated plasma levels of (**a**) alanine transaminase (ALT), (**b**) aspartate transaminase (AST), and (**c**) bilirubin for the four cimaglermin alfa-treated subjects and the placebo-treated subject included in the DILIsym analyses. Subjects included in the DILIsym analyses consist of 2 subjects whom met FDA Drug-Induced Liver Injury (DILI) Guidance stopping criteria (Subjects 8 and 12), as well as 2 subjects with elevated serum aminotransferases that fell short of meeting FDA DILI Guidance stopping criteria (Subjects 7 and 11), and one placebo-treated subject (Subject 6). Subjects 6, 7, 8, 11, and 12 were also included in the set of 12 subjects included in the serum biomarker analysis (**Figure 1**). Simulations in the baseline human in DILIsym were performed with 100% necrosis as the cell death modality. The ALT model was optimized to the cimaglermin alfa ALT clinical data. AST and bilirubin data were not used for the optimization; plasma AST and bilirubin levels were simulated based on the amount of hepatocyte injury optimized to ALT dynamics. Closed black circles represent clinical data. Solid red lines represent simulated results due to 100% necrosis.